Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116630 | 0.92 | ALDH1A1 (0.78) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL27368115 | 0.92 | GRM5 (0.62) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL28702811 | 0.90 | RAB9A (0.65) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL5783791 | 0.87 | ALDH1A1 (0.71) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL3427705 | 0.86 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL3427969 | 0.86 | ALDH1A1 (0.70) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL19691212 | 0.85 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL19691213 | 0.85 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL4414127 | 0.85 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL10143960 | 0.85 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | ALDH1A1 3540/4885L3MBTL1 1756/4885HTT 4051/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ALDH1A1 1168/4885L3MBTL1 3165/4885HTT 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.